Exclusion of two candidate loci for autosomal recessive nemaline myopathy

Esa Tahvanainen, Alan H Beggs, Carina Wallgren-Pettersson

Abstract
The putative gene for autosomal recessive nemaline myopathy has not been mapped, cloned, or otherwise characterised. We used linkage analysis with polymorphic CA repeats to test for the involvement of two candidate loci, APOA2 and ACTN2. Based on the segregation in five families both candidate loci could be excluded.

Congenital nemaline myopathy (CNM), first described in 1963 by Conen et al1 and Shy et al.2 exists in an autosomal recessive and an autosomal dominant form.34 Both are characterised by generalised muscle weakness and nemaline bodies in the muscle fibres. Laing et al.6 suggested linkage of the gene for the autosomal dominant form to chromosome 1 in a large Australian family with a maximum lod score of 3-8 at zero recombination for the polymorphic marker APOA2. As far as we know no linkage studies have been published to date on the autosomal recessive form.

α-actinin is regarded as a major constituent of the nemaline bodies.5 Therefore, the genes for human muscle specific α-actinin, ACTN2 on chromosome 1q42-q43 and ACTN3 on chromosome 11q13-q14, have been suggested as candidate genes for CNM.7 These genes have been cloned but an intragenic polymorphism is only available for ACTN2.8

We studied five families, each with two children affected by autosomal recessive CNM. Three of the families were Finnish,9 one Welsh, and one Danish. All 10 patients showed a clinical picture consistent with CNM: the muscle weakness was most pronounced in the face, the flexors of the neck and trunk, the dorsiflexors of the feet, and the extensors of the toes. All showed nemaline bodies and predominance of type 1 fibres in their muscle biopsies, except for the sister of one of the index cases, who had a clinical picture identical to that of her affected brother and did not undergo muscle biopsy.

DNA from blood lymphocytes of the patients and their parents were studied with an intragenic ACTN29 and an APOA210 CA repeat polymorphism. Microsatellite PCR conditions for a reaction volume of 10 μl were as follows: 30 ng target DNA, 0·3 units DNA polymerase (Finnzymes, Espoo, Finland), 25 ng primers ACTN2 or APOA2, 10 mmol/l Tris–HCl (pH 8·8 at 20°C), 1·5 mmol/l MgCl2, 50 mmol/l KCl, 0·1% Triton X-100, 200 μmol/l dATP, dGTP, and dTTP, 3 μmol/l dCTP, and 0·7 μCi α 32P dCTP (300 Ci/mmol, Amersham). The reactions were overlaid with mineral oil and temperature cycling conditions were as follows: 94°C for three minutes to denature, followed by 30 cycles at 94°C, 55°C, and 72°C each for one minute, with the final elongation time extended to five minutes. The reaction products were mixed with an equal volume of formamide loading buffer, 5 μl aliquots were electrophoresed on standard 6% denaturing sequencing gels, and autoradiographs were made using x ray film. Lod scores were calcu-
lated by the MLINK program of the LINKAGE package.11

For CA marker ACTN2 three families showed recombination between the marker and the disease gene (figure), two families were uninformative, and the lod score at a recombination fraction of 0·01 was −3·62. All families showed recombination between marker APOA2 and the disease gene, the lod scores being −7·83 at a recombination fraction of 0·01 and −2·23 at 0·1.

We conclude that ACTN2 is not the gene causing autosomal recessive CNM and the disease gene does not segregate with the locus APOA2.

The authors are grateful to Professor Albert de la Chapelle, Department of Medical Genetics, University of Helsinki, for critical reading of the manuscript, to Dr Helen Hughes, Institute of Medical Genetics, University of Wales College of Medicine, for providing facilities to study the Welsh family, to Dr Tim Helliwell, University of Liverpool, UK, for studying the muscle biopsies of the Welsh patients, to Dr Flemming Juul Hansen, University Hospital, Section of Neuropediatrics, Copenhagen, Denmark, for providing facilities to study the Danish family, and Nigel Laing, Australian Neuromuscular Research Institute, Department of Pathology, QUE Medical Centre, Nedlands, Australia, for helpful discussions. Dr Alan H Beggs was supported in part by the Charles H Hood Foundation, Boston, Massachusetts and Dr Carina Wallgren-Pettersson by the Finska Lakareallianset, Finland.

1 Conen PE, Murphy EG, Donohue WL. Light and electron microscopic studies of "myonemal" in a child with hypotonia and muscle weakness. Can Med Assoc J 1965;89:985-6.